A Study of MHB088C Combined With MHB039A in Patients With Advanced Malignant Solid Tumors
A phase 1/2 trial of QLC5508 in advanced solid tumours, run by Minghui Pharmaceutical (Hangzhou) Ltd, now recruiting.
Overview
A Study of MHB088C Combined With MHB039A in Patients With Advanced Malignant Solid Tumors is a phase 1/2 interventional study registered as NCT07126665 by Minghui Pharmaceutical (Hangzhou) Ltd, with 116 participants planned, started 2025-09-18 and due to reach its primary completion in 2029-08. Interventions recorded: MHB088C for Injection and MHB039A for Injection.
Similar pages
not linked directly; found by shared links- TrialA Study of MHB039A for Advanced Solid Tumor
Shares MHB039A, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of MHB036C Combined With MHB039A in Patients With Advanced Breast Cancer or Other Advanced Malignant Solid Tumors
Shares MHB039A, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialStudy of MHB088C for Patients With Advanced Solid Malignant Tumors
Shares QLC5508, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of MHB036C Combined With Anti-tumor Therapies in Patients With Advanced Lung Cancer
Shares MHB039A, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of QLC5508 Combinations in Patients With Advanced Solid Tumors
Shares QLC5508, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialInvestigation of a Therapeutic Vaccine (ACIT-1) in Cancer
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialPlasmodium Immunotherapy for Advanced Malignant Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialFirst-in-Human Study of ICT01 in Patients With Advanced Cancer
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.